RxElite Financial Statements From 2010 to 2026

RXEI Stock  USD 0.0001  0.00  0.00%   
RxElite's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing RxElite's valuation are provided below:
Gross Profit
1.2 M
Profit Margin
(2.80)
Market Capitalization
35.9 K
Enterprise Value Revenue
0.0034
Revenue
10.4 M
We have found one hundred sixteen available trending fundamental ratios for RxElite, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of RxElite recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 20.4 K. The RxElite's current Enterprise Value is estimated to increase to about (10.4 M)

RxElite Total Revenue

2.4 Million

Check RxElite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RxElite's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.6 M or Total Revenue of 2.4 M, as well as many indicators such as Price To Sales Ratio of 0.0077, Dividend Yield of 0.0 or PTB Ratio of 0.0039. RxElite financial statements analysis is a perfect complement when working with RxElite Valuation or Volatility modules.
  
Build AI portfolio with RxElite Stock
Check out the analysis of RxElite Correlation against competitors.
For more detail on how to invest in RxElite Stock please use our How to Invest in RxElite guide.

RxElite Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.9 M24.5 M20.5 M
Pretty Stable
Other Current Liabilities12 K13.5 K14.7 K
Slightly volatile
Total Current LiabilitiesM6.4 M7.4 M
Slightly volatile
Accounts Payable4.4 M6.6 M5.4 M
Slightly volatile
Cash12.2 M11.6 M9.7 M
Slightly volatile
Long Term Debt47.8 K50.3 K684.3 K
Slightly volatile
Net Receivables1.5 M872.2 K1.2 M
Slightly volatile
Inventory6.3 M8.5 M7.2 M
Slightly volatile
Other Current Assets1.1 M1.3 M1.4 M
Slightly volatile
Other Stockholder Equity3.5 M5.9 M4.8 M
Slightly volatile
Total Liabilities10.5 M8.1 M9.8 M
Slightly volatile
Short and Long Term Debt219 K230.6 K638.4 K
Slightly volatile
Total Current Assets13.7 M21.3 M17.9 M
Pretty Stable
Short Term Debt219 K230.6 K638.4 K
Slightly volatile
Intangible Assets55.8 K60.5 K66.4 K
Slightly volatile
Common Stock60.6 K111.2 K91.9 K
Pretty Stable
Property Plant Equipment2.2 M2.1 M1.8 M
Slightly volatile
Other Assets493 K961.8 K777.8 K
Pretty Stable
Other Liabilities1.4 M1.5 M1.7 M
Slightly volatile

RxElite Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.6 M10.4 M8.6 M
Pretty Stable
Total Revenue2.4 M2.5 M4.1 M
Slightly volatile
Gross Profit123.1 K129.6 K213.9 K
Slightly volatile
Research Development3.8 M3.6 MM
Slightly volatile
Cost Of Revenue2.3 M2.4 M3.9 M
Slightly volatile
Total Operating Expenses16 M13.6 M15.7 M
Slightly volatile

RxElite Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Cash9.3 M8.9 M7.5 M
Slightly volatile
Net Borrowings11.6 M11 M9.2 M
Slightly volatile
Depreciation527.6 K502.5 K423.1 K
Slightly volatile
Capital Expenditures2.2 M2.1 M1.8 M
Slightly volatile
Total Cash From Financing Activities27.7 M26.4 M22.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.00770.0140.0145
Very volatile
PTB Ratio0.00390.00410.0078
Slightly volatile
Days Sales Outstanding71.42113117
Very volatile
Book Value Per Share0.190.180.1847
Slightly volatile
Average Payables2.7 M2.6 M2.7 M
Slightly volatile
Capex To Depreciation4.114.864.3685
Slightly volatile
PB Ratio0.00390.00410.0078
Slightly volatile
ROIC0.50.760.7902
Very volatile
Inventory Turnover0.40.425.3775
Slightly volatile
Days Of Inventory On Hand951906938
Slightly volatile
Payables Turnover0.510.541.0111
Slightly volatile
Average InventoryK6.7 K7.3 K
Slightly volatile
Research And Ddevelopement To Revenue0.91.011.0996
Slightly volatile
Capex To Revenue0.620.590.615
Slightly volatile
Cash Per Share0.150.1620.1511
Slightly volatile
Days Payables Outstanding740704732
Slightly volatile
EV To Operating Cash Flow0.670.640.6791
Slightly volatile
Intangibles To Total Assets0.00250.00280.0031
Slightly volatile
Net Debt To EBITDA0.550.520.5453
Slightly volatile
Current Ratio1.782.332.4781
Very volatile
Tangible Book Value Per Share0.190.180.1838
Slightly volatile
Receivables Turnover5.263.343.3377
Pretty Stable
Shareholders Equity Per Share0.190.180.1847
Slightly volatile
Debt To Equity0.03840.04320.0471
Slightly volatile
Capex Per Share0.0280.02660.0278
Slightly volatile
Graham Net Net0.08410.08010.0831
Slightly volatile
Revenue Per Share0.09320.05180.0513
Very volatile
Interest Debt Per Share0.00760.00850.0093
Slightly volatile
Debt To Assets0.02220.0250.0273
Slightly volatile
Graham Number0.05420.0610.0665
Slightly volatile
Operating Cycle1.1 KK1.1 K
Slightly volatile
Price Book Value Ratio0.00390.00410.0078
Slightly volatile
Days Of Payables Outstanding740704732
Slightly volatile
Operating Profit Margin4.133.934.0735
Slightly volatile
Company Equity Multiplier1.911.991.7612
Slightly volatile
Long Term Debt To Capitalization0.00360.00410.0044
Slightly volatile
Total Debt To Capitalization0.03660.04120.045
Slightly volatile
Return On Capital Employed0.50.780.8139
Very volatile
Debt Equity Ratio0.03840.04320.0471
Slightly volatile
Ebit Per Revenue4.133.934.0735
Slightly volatile
Quick Ratio2.021.81.6096
Slightly volatile
Net Income Per E B T0.520.590.6412
Slightly volatile
Cash Ratio1.341.271.3213
Slightly volatile
Cash Conversion Cycle330314326
Slightly volatile
Days Of Inventory Outstanding951906938
Slightly volatile
Days Of Sales Outstanding71.42113117
Very volatile
Price To Book Ratio0.00390.00410.0078
Slightly volatile
Fixed Asset Turnover1.681.762.9853
Slightly volatile
Debt Ratio0.02220.0250.0273
Slightly volatile
Price Sales Ratio0.00770.0140.0145
Very volatile
Asset Turnover0.140.150.4525
Slightly volatile
Gross Profit Margin0.0560.05890.0804
Slightly volatile
Price Fair Value0.00390.00410.0078
Slightly volatile

RxElite Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.4 K39.3 K39.9 K
Very volatile

About RxElite Financial Statements

Investors use fundamental indicators, such as RxElite's revenue or net income, to determine how well the company is positioned to perform in the future. Although RxElite's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Revenue2.5 M2.4 M
Cost Of Revenue2.4 M2.3 M
Research And Ddevelopement To Revenue 1.01  0.90 
Capex To Revenue 0.59  0.62 
Revenue Per Share 0.05  0.09 
Ebit Per Revenue 3.93  4.13 

Currently Active Assets on Macroaxis

When determining whether RxElite offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of RxElite's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rxelite Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rxelite Stock:
Check out the analysis of RxElite Correlation against competitors.
For more detail on how to invest in RxElite Stock please use our How to Invest in RxElite guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RxElite. If investors know RxElite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RxElite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.096
Quarterly Revenue Growth
3.321
Return On Assets
(0.38)
Return On Equity
(2.94)
The market value of RxElite is measured differently than its book value, which is the value of RxElite that is recorded on the company's balance sheet. Investors also form their own opinion of RxElite's value that differs from its market value or its book value, called intrinsic value, which is RxElite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RxElite's market value can be influenced by many factors that don't directly affect RxElite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RxElite's value and its price as these two are different measures arrived at by different means. Investors typically determine if RxElite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RxElite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.